Lupin Limited
LUPIN
株式のランク
#2146
Lupin Limited is a pharmaceutical firm dedicated to the creation,... Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
株価
$20.35
時価総額
$9.30B
変化（1日）
-5.06%
変化（1年）
-7.79%
国
IN
取引 Lupin Limited (LUPIN)
カテゴリー
Healthcare
Lupin Limited（LUPIN）の収益
Jun 2026 時点の収益 TTM: $3.30B
Lupin Limited の最新の財務報告によると、現在の収益 (TTM) は $3.30B です。2025 年には $2.66B の収益があり、これは 2024 年の $2.40B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Lupin Limited の収益履歴（2004 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $3.30B | 24.28% |
| 2025 | $2.66B | 10.63% |
| 2024 | $2.40B | 18.51% |
| 2023 | $2.03B | -6.30% |
| 2022 | $2.16B | 4.34% |
| 2021 | $2.07B | 1.49% |
| 2020 | $2.04B | -3.36% |
| 2019 | $2.11B | -12.84% |
| 2018 | $2.42B | -9.52% |
| 2017 | $2.68B | 25.55% |
| 2016 | $2.13B | 4.23% |
| 2015 | $2.05B | -3.94% |
| 2014 | $2.13B | 20.07% |
| 2013 | $1.77B | 27.03% |
| 2012 | $1.40B | 9.08% |
| 2011 | $1.28B | 20.48% |
| 2010 | $1.06B | 42.91% |
| 2009 | $743.76M | 9.97% |
| 2008 | $676.32M | 45.59% |
| 2007 | $464.54M | 22.04% |
| 2006 | $380.66M | 31.80% |
| 2005 | $288.82M | 3.17% |
| 2004 | $279.94M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 100.37% |
IN
|
